Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2014 - 2021)

Enanta Pharmaceuticals has reported Long-Term Deferred Tax for 8 years, with the latest figure at $345000.0 in Q2 2021.

• For the quarter ending Q2 2021, Long-Term Deferred Tax fell 97.74% year-over-year to $345000.0; the trailing twelve-month figure through Jun 2021 stood at $345000.0 (down 97.74% YoY), and the FY2020 full-year result was $345000.0, down 96.96% from the prior year.
• Long-Term Deferred Tax for Q2 2021 stood at $345000.0, roughly flat from $345000.0 in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $17.7 million in Q2 2017, with the low at $345000.0 in Q3 2020.
• Historically, Long-Term Deferred Tax has averaged $8.5 million across 5 years, with a median of $9.2 million in 2018.
• Annual changes were most pronounced in 2017 — Long-Term Deferred Tax jumped 203.32% — and 2021, when it sank 97.74%.
• Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $7.6 million in 2017, then climbed by 22.2% to $9.2 million in 2018, then gained by 15.22% to $10.7 million in 2019, then sank by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
• The last three Long-Term Deferred Tax figures came in at $345000.0 (Q2 2021), $345000.0 (Q1 2021), and $345000.0 (Q4 2020), per Business Quant data.